Neuroglia are homeostatic cells of the central nervous system, which are ultimately involved in many (if not all) forms of neuropathology.^[@bib1],\ [@bib2]^ The pathological potential of neuroglial cells was recognized already by Rudolf Virchow, who comprehended that neuroglia 'is one of the most frequent seats of morbid change\'.^[@bib3]^ Pathologically remodelled glial cells associated with various types of neurological conditions have been subsequently identified by prominent histopathologists such as Nissl, Frommann and Alzheimer (see Kettenmann and Verkhratsky^[@bib4]^ for a historical review). Alzheimer^[@bib5]^ made the first descriptions of pathological glia in the context of dementia and identified glial cells as morphological components of senile plaques.

Astrocytes are the principal homeostatic cells of the central nervous system. The role of astroglia in the pathogenesis of Alzheimeŕs disease (AD) remains generally unknown although the interest in astroglial remodelling in the course of neurodegeneration has increased substantially during the last decade.^[@bib1],\ [@bib6],\ [@bib7],\ [@bib8],\ [@bib9]^ AD is considered to be one of the most prevalent forms of dementia in humans,^[@bib10]^ the symptoms of which are manifested by progressive cognitive impairment. Histopathological changes associated with AD include senile plaques, neurofibrillary tangles, neuroinflammation, altered synaptic connectivity and neuronal death.^[@bib11],\ [@bib12]^ The loss of synapses, in particular, is considered to be the earliest AD-associated cellular pathology responsible for early signs of cognitive failure.^[@bib13],\ [@bib14]^ This loss of synapses may reflect functional downfall of astrocytes that are generally responsible for synaptic maintenance and homeostasis of ions and neurotransmitters, the latter being critical for synaptic transmission. Indeed, recent data indicated atrophic changes in astroglia at the early (i.e., pre-plaque) stages of AD-like pathology in transgenic model animals, which may account for the deficient synaptic connectivity.^[@bib9],\ [@bib15],\ [@bib16]^ At the later stages, the emergence of *β*-amyloid depositions and formation of senile plaques trigger reactive astrogliosis, which mainly occurs in cells directly associated with *β*-amyloid plaques.^[@bib15],\ [@bib16]^

The spatio-temporal progression of AD is well identified, with the entorhinal cortex (EC) being the very first area to be affected by the pathology.^[@bib17]^ Neurons in superficial layers of the EC innervate all hippocampal subregions, including the dentate gyrus (DG), CA3, CA1 and subiculum via the perforant pathway; synaptic connections between mossy fibers of DG and CA3 neurons and Schaffer collaterals from CA3 to CA1 neurons complete the forward hippocampal circuit.^[@bib18]^ In AD, a significant loss of neurons in EC layer II occurs at the early stages.^[@bib19]^ In AD patients, the EC could be the region from which the pathological process spreads towards other brain regions; this has been initially hypothesized because expression of APP, the precursor of *β*−amyloid, was higher in EC layer II neurons than in other brain areas.^[@bib20]^ Moreover, APP synthesized by EC neurons is transported via the perforant pathway to presynaptic terminals in DG. A profound reduction in *β*-amyloid burden was observed in DG, following unilateral severance of the perforant pathway.^[@bib21]^

Our previous morphological analysis^[@bib22]^ found a remarkable difference in the AD-associated behavior of astrocytes in the EC. In contrast to the hippocampus, where reactive astrocytes were a prominent feature of *β*-amyloid depositions, in EC astrocytes failed to show any reactivity and were not specifically associated with *β*-amyloid. In this study, we analyzed Ca^2+^ signalling and the metabotropic Ca^2+^ signalling molecular toolkit in EC and hippocampal astrocytes *in vitro* in cell cultures. We found that these astroglial populations have distinct reactions to *β*-amyloid treatment that may account for differences in their reactivity in the pathological context.

Results
=======

Astroglial cultures derived from the EC and hippocampus are morphologically different
-------------------------------------------------------------------------------------

The morphology of astroglial cells from the EC and hippocampus, when maintained *in vitro* for the first 3--5 days, was characteristically different. In hippocampal cultures, majority of the cells were large and flat (or star-shaped), whereas in EC cultures many cells were thin and oblong with almost needle-like morphology. [Figure 1a](#fig1){ref-type="fig"} shows the differences in morphology between cultured astrocytes derived from the hippocampus and astrocytes derived from the EC. Both types of cells were positive to glial fibrillary acidic protein (GFAP) immunostaining, confirming thus their astroglial nature ([Figure 1b](#fig1){ref-type="fig"}). The morphology of EC astrocytes maintained in culture was similar to their appearance *in situ* ([Figure 1c](#fig1){ref-type="fig"}).^[@bib22]^ The quantification of the number of thin and oblong cells shows a significantly higher percentage of this morphological profile in EC cultures ([Figures 1a](#fig1){ref-type="fig"}). The overall morphological features of astrocytes from non-Tg and 3xTg-AD mice did not show any significant differences ([Figure 1b](#fig1){ref-type="fig"}).

Of interest, in older cultures, we also observed different proportions of large flat 'proliferating\' cells and star-shaped 'reactive\' cells (expressing high levels of GFAP) in hippocampal *versus* EC cultures, the number of 'reactive\' astrocytes being substantially higher in the former (the % of star-shaped cells in hippocampal cultures was 21.3±3.07, whereas that in EC cultures was 9.65±2.05, *P*\<0.05; *n*=240 cells from four cultures).

A*β* oligomers differentially affect the expression of mGluR5 and InsP~3~R1 in astrocytes from EC and hippocampus
-----------------------------------------------------------------------------------------------------------------

Previously we have demonstrated that A*β*-oligomers affect the calcium signalling cascade in astrocytes derived from rat hippocampus, by increasing the expression of metabotropic glutamate receptor type 5 (mGluR5) and its downstream receptor, InsP~3~ receptor type 1 (InsP~3~R1), which resulted in an increased amplitude of Ca^2+^ responses to selective mGluR5 agonist, DHPG.^[@bib23]^ Here, we compared the effects of A*β* oligomers on the expression of mGluR5 and InsP~3~R1 in astrocytes derived from the hippocampus and EC of 7-day-old non-Tg and 3xTg-AD mice.

First, we confirmed the presence of these receptors in astrocytes cultured from both the hippocampus and the EC of non-Tg control mice by immunocytochemistry ([Figure 2a](#fig2){ref-type="fig"}). Treatment with 100 nM A*β*~1-42~ induced strong and rapid upregulation of mGluR5 and InsP~3~R1 expression only in hippocampal astrocytes derived from non-Tg mice. This increase in receptor expression was already present after 48 h (data not shown), and was even more pronounced after 72 h of treatment ([Figure 2b](#fig2){ref-type="fig"}, upper panel).

In contrast, A*β*-treatment of astrocytes isolated from the EC of non-Tg mice did not affect the expression of either mGluR5 or InsP~3~R1 ([Figure 2b](#fig2){ref-type="fig"}, lower panel). Further, A*β*-oligomers had no effect on the expression of both receptors in astrocytes isolated from the hippocampus and EC of 3xTg-AD mice, although the basal levels of these proteins were different. In both EC and hippocampal astrocytes obtained from these mice, basal expression of mGluR5 was lower, whereas that of InsP~3~R1 was higher compared with non-Tg control mice ([Figure 2b](#fig2){ref-type="fig"}).

Metabotropic glutamatergic calcium signalling is differentially affected by A*β* in EC and hippocampal astrocytes
-----------------------------------------------------------------------------------------------------------------

The group I mGluR family is composed of two members (mGluR1 and mGluR5). Our previous study revealed that mGluR5 was the sole receptor responsible for DHPG-induced Ca^2+^ transients in astrocytes.^[@bib23]^ Moreover, mGluR1 is either absent or present at low levels in these cells, as also has been observed by others.^[@bib24],\ [@bib25]^

After treating the astrocytes from the EC and hippocampus of non-Tg and 3xTg-AD mice with 100 nM A*β*~1-42~ oligomers, cells were loaded with the calcium probe Fluo4-AM, and their responses to 100 nM DHPG (15 s) were analyzed. [Figures 3a and b](#fig3){ref-type="fig"} show representative traces of DHPG-induced Ca^2+^ responses in astrocytes derived from the hippocampus and EC of non-Tg and 3xTg-AD mice. Treatment with A*β* significantly increased the amplitude of DHPG-responses in hippocampal astrocytes when compared with control. The same treatment, however, did not modify Ca^2+^ responses in EC astrocytes derived from the same mice ([Figure 3b](#fig3){ref-type="fig"}). The integrals ('area under the curve\') of \[Ca^2+^\]~i~ transient that represent the overall Ca^2+^ load of stimulated cells were 26.20±5.77 in non-Tg control hippocampal astrocytes *versus* 46.09±7.41 in non-Tg A*β*-treated hippocampal astrocytes (*P*\<0.05), and 16.57±5.32 in non-Tg control EC astrocytes *versus* 14.36±5.35 in non-Tg A*β*-treated EC astrocytes (*P*=0.75) ([Figure 3c](#fig3){ref-type="fig"}, *n*=150 cells from five different cultures for each experimental protocol).

In astrocytes from 3xTg-AD animals, A*β* oligomers did not affect the DHPG-mediated Ca^2+^ responses, neither in hippocampal nor in EC astrocytes ([Figure 3c](#fig3){ref-type="fig"}). The overall amplitudes of DHPG-induced Ca^2+^ responses in EC astrocytes were lower than in cells from the hippocampus (\[Ca^2+^\]~i~ transient integral 28.65±5.76 in 3xTg-AD control hippocampal astrocytes *versus* 24.51±9.33 in 3xTg-AD A*β*-treated hippocampal astrocytes (*P*=0.66); and 11.13±6.88 in 3xTg-AD control EC astrocytes *versus* 18.70±8.25 in 3xTg-AD-treated A*β* EC astrocytes (*P*=0.44), *n*=150 cells from five cultures).

Purinergic calcium signalling is differentially affected by A*β* in EC and hippocampal astrocytes
-------------------------------------------------------------------------------------------------

Ca^2+^ responses to ATP stimulation were examined in astrocytes from the EC and hippocampus subjected to 72 h of incubation with A*β*~1--42~ oligomers. Treatment with A*β* resulted in an increase of ATP-induced Ca^2+^ signals only in astrocytes isolated from the hippocampus of non-Tg mice compared to control cells ([Figure 4](#fig4){ref-type="fig"}). Mean values for integrals of \[Ca^2+^\]~i~ transients were 15.30±1.50 in non-Tg control hippocampal astrocytes *versus* 29.11±2.12 in non-Tg A*β*-treated hippocampal astrocytes (*P*\<0.01); and 9.64±3.68 in non-Tg control EC astrocytes *versus* 19.60±6.56 in non-Tg A*β*-treated EC astrocytes (*P*=0.37); *n*=150 cells from five cultures).

3xTg-AD hippocampal astrocytes showed basal calcium deregulation when stimulated with ATP
-----------------------------------------------------------------------------------------

Treatment with A*β* did not affect ATP-induced Ca^2+^ responses in astrocytes from 3xTg-AD mice from both the EC and hippocampus ([Figure 4](#fig4){ref-type="fig"}; integrals of \[Ca^2+^\]~i~ transients were 29.15±2.05 in 3xTg-AD control hippocampal astrocytes *versus* 32.56±3.40 in 3xTg-AD A*β*-treated hippocampal astrocytes (*P*=0.34); and 15.75±6.57 in 3xTg-AD control EC astrocytes *versus* 30.79±11.98 in 3xTg-AD A*β*-treated EC astrocytes (*P*=0.36); *n*=120 cells from four different cultures). However, in hippocampal astrocytes derived from 3xTg-AD mice, the amplitudes of ATP-calcium responses in control cells were significantly higher compared with that measured in astrocytes derived from non-Tg mice ([Figure 4c](#fig4){ref-type="fig"}, integrals of \[Ca^2+^\]~i~ transients being 15.30±1.50 *versus* 29.15±2.05, *P*\<0.01). In that, the amplitudes of ATP-mediated Ca^2+^ responses in hippocampal astrocytes derived from 3xTg-AD mice (\[Ca^2+^\]~i~ 29.15±2.05) were comparable to the amplitudes of ATP-mediated Ca^2+^ responses in A*β*-treated hippocampal astrocytes derived from non-Tg mice (\[Ca^2+^\]~i~ 29.11±2.12). In contrast, there was little difference between the amplitudes of ATP-mediated Ca^2+^ responses in astrocytes from the EC of non-Tg mice and 3xTg-AD mice ([Figure 4c](#fig4){ref-type="fig"}, integrals of \[Ca^2+^\]~i~ transients were 9.64±3.68 *versus* 15.75±6.57, *P*=0.13).

Discussion
==========

In this study, we have investigated the effect of A*β* oligomers on calcium signalling cascades in astrocytes derived from two brain regions predicted to be principally involved in AD pathology, namely, the hippocampus and EC. The key findings presented in this paper are: (1) astrocytes derived from the hippocampus and EC retain their morphological phenotype *in vitro* for several days after isolation; (2) astrocytes from these two different regions have distinct Ca^2+^ signalling toolkits that are differentially affected by A*β*-oligomers. Of particular interest are: (i) treatment of healthy astrocytes with A*β* increased the expression of mGluR5 and InsP~3~R1 only in hippocampal astrocytes; (ii) in agreement with this, A*β* treatment potentiated Ca^2+^ responses mediated through mGluR5/InsP~3~Rs cascade only in hippocampal and not in EC astrocytes; and (iii) treatment with A*β* did not affect Ca^2+^ signalling in astrocytes isolated from the transgenic animal model of AD.

Our previous results showed a concomitant occurrence of astroglial atrophy, as a generalized process, and astrogliosis of the astrocytes surrounding senile plaques in hippocampus of 3xTg-AD mice.^[@bib15]^ Subsequently, we found that although the astroglial atrophy persisted in the EC and in the prefrontal cortex, the astrogliotic reaction in the EC was absent.^[@bib22],\ [@bib26]^ We failed to observe any signs of hypertrophy in EC astrocytes in both non-Tg and 3xTg-AD animals at all ages up to 18 months. The present study was designed to determine functional differences between astrocytes from different brain areas.

First, we confirmed in primary cell culture our previous *in situ* results, that astrocytes even after isolation from the brain retain their morphological idiosyncrasies for 3--5 days *in vitro*: astrocytes from the EC remained characteristically needle-shaped, whereas hippocampal astrocytes had more of a star-like appearance. Furthermore, we observed that overall percentage of stellate astroglial cells was higher in hippocampal cultures, which may be indicative of their higher intrinsic reactivity.

Different hypotheses are recognized for AD pathology, because of its multifactorial trait. One of them is the 'amyloid hypothesis\', in which the main cause of AD is the deposition of amyloid-*β* plaques (senile plaques) that disrupted the normal activity of neurons in the brain.^[@bib27]^ Another hypothesis assumed the pathological role of abnormal Ca^2+^ homeostasis; this 'calcium hypothesis\' of neurodegeneration^[@bib28],\ [@bib29],\ [@bib30],\ [@bib31],\ [@bib32],\ [@bib33]^ postulates that A*β* affects calcium homeostasis/signalling in neurons that results in long-lasting overload of the cytoplasm with Ca^2+^ in parallel with disrupted Ca^2+^ handling by the endoplasmic reticulum, the two processes initiating metabolic and biosynthetic stress, ultimately leading to neuronal death.^[@bib31],\ [@bib34],\ [@bib35]^

For these reasons, the present study was focused on calcium signalling pathways, which are critically involved in astroglial functions in health and disease.^[@bib36]^ Disruption of Ca^2+^ homeostasis is implicated in many forms of neuropathology,^[@bib37],\ [@bib38],\ [@bib39],\ [@bib40]^ and in particular Ca^2+^ deregulation is considered to be of fundamental importance for cellular pathology in AD.^[@bib31],\ [@bib32],\ [@bib35],\ [@bib41]^ The key pathway of astroglial Ca^2+^ signalling is represented by a metabotropic route that comprises seven transmembrane domain G protein-coupled receptors (of which glutamate and purinoceptors are the most abundant in glia), phospholipase C and InsP~3~Rs located at the endomembrane.^[@bib36]^

We established that treatment with pathologically relevant (100 nM) concentrations of A*β* affects the metabotropic Ca^2+^ signalling toolkit in EC and hippocampal astrocytes in a very different way. Exposure to A*β* increased the expression of both mGluR5 and InsP~3~R1 in hippocampal astrocytes. This increase in expression of Ca^2+^ signalling molecules resulted in an increase in the amplitude of \[Ca^2+^\]~i~ transients following stimulation with mGluR5 agonist DHPG or ATP. In contrast, treatment with A*β* neither affected expression of metabotropic Ca^2+^ signalling toolkit, nor modified the parameters of DHPG and ATP-induced Ca^2+^ transients in EC astrocytes.

Of significance, the effects of A*β* treatment changed completely in a pathological context in that exposure of EC and hippocampal astrocytes derived from 3xTg-AD animals to A*β* affected neither expression of mGluR5 and InsP~3~R1, nor the parameters of metabotropically stimulated \[Ca^2+^\]~i~ transients. At the same time, basal levels of expression of mGluR5 and InsP~3~R1 were substantially modified in pathologically remodelled astrocytes compared with non-transgenic controls. Similarly, stimulation of astrocytes with agonists triggered \[Ca^2+^\]~i~ transients with higher amplitudes compared with cells from healthy wild-type controls. We can therefore suggest that expression of AD-related mutant genes deregulates Ca^2+^ homeostasis and signalling in astroglia.

In conclusion, we have shown that astrocytes from different brain regions display different patterns of response to exogenous A*β*. This transpires to different responses of the Ca^2+^ signalling toolkit to a pathological context and may account for the different reactivities of astroglia observed in the whole tissue to the progression of AD. We may therefore speculate that the distinct responsiveness of Ca^2+^ signalling machinery in EC astrocytes can be linked to their inability to mount astrogliotic response to *β*-amyloid deposition, which in turn can underlie the higher vulnerability of EC to AD-like pathology. This far-reaching speculation naturally requires future experiments and, above all, analysis of \[Ca^2+^\]~i~ signalling in astrocytes from different brain regions *in situ* and *in vivo*.

Materials and Methods
=====================

All animal procedures were carried out in accordance with the United Kingdom Animals (Scientific Procedures) Act of 1986 under the license from Home Office. All efforts were made to reduce the number of animals by following the 3R\'s.

Animal models
-------------

Experiments were performed on 3xTg-AD mice, introduced by Frank LaFerla and Salvatore Oddo in 2003.^[@bib42]^ These mice were developed on the mixed 129/C57BL6 background and harbor APP~swe~, PS1M146V and TauP301L mutations. The 3xTg-AD animals show major hallmarks of AD represented by senile plaques and neurofibrillary tangles. The non-Tg (non-transgenic) control mice were from the same strain and the same genetic background. All 3xTg-AD and non-Tg littermates were from homozygous breeders.

Primary astrocyte cultures and A*β* treatment
---------------------------------------------

The EC and hippocampus were dissected from the brains of 7-day-old non-Tg and 3xTg-AD mice. Purified glial cell cultures were prepared as described previously.^[@bib43]^ Isolated astrocytes were seeded in Dulbecco\'s modified Eagle\'s medium (DMEM) with 4.5 g/l 𝒟-glucose (Gibco 11960-044; Life Sciences Ltd, Paisley, UK), supplemented with 10% fetal bovine serum (FBS), 2 mg/ml glutamine, 10 U/ml penicillin and 100 *μ*g/ml streptomycin (Sigma, Dorset, UK). The cells were grown until confluence (2--4 days) and then were plated on coverslips coated with 0.1 mg/ml poly-ℒ-lysine. The purity of cultures was assayed by immunostaining with anti-MAP2 (neuronal marker) and anti-GFAP (glial marker) and anti-Iba1 (microglial marker). Both neurons and microglia accounted for \<0.5% of all cells.

Astrocytes were treated after 4 days *in vitro* (DIV) with 100 nM of A*β*~1--42~ oligomers for 48 or 72 h, and then analyzed by calcium imaging or western blot. As negative controls, we used an inactive form of amyloid protein A*β*~1--42~ (100 nM) and vehicle (physiological saline); neither had any effect on expression of components of the Ca^2+^ signalling toolkit and parameters of Ca^2+^ signals.

Preparation of A*β*~1--42~ oligomers
------------------------------------

A*β*~1--42~ peptide was oligomerized as described previously,^[@bib44]^ with some modifications. Briefly, 1 mg of A*β* was diluted in 1 ml of 1,1,1,3,3,3-hexa-fluoro-2-propanol (HFIP, 52512 Fluka, Sigma) and incubated for 1 h at 37 °C. Then, HFIP was lyophilized by using a SpeedVac concentrator (Thermo Fisher Scientific, Loughborough, UK). The A*β* pellet was subsequently dissolved in 5 mM DMSO and then diluted to 100 *μ*M in ice-cold cell phosphate buffer. The solution was incubated overnight at 4 °C, which favoured oligomerization. Aliquots were stored at −20 °C. The presence of oligomers was verified by loading the A*β* preparation in a native gel stained with Coomassie.

Immunocytochemistry
-------------------

Cultured astrocytes were fixed in 4% formaldehyde in PBS for 7 min at room temperature. Subsequently, primary and secondary antibodies were applied in GDB buffer, as described previously.^[@bib45]^ Fluorescence images were acquired using a Zeiss Axiovert 25 microscope equipped with a Zeiss Axiocam HRc camera (Carl Zeiss Ltd, Welwyn Garden City, UK). Green fluorescence was detected at 515--565 nm following excitation at 450--490 nm; red fluorescence was detected at 590 nm following excitation at 546 nm; blue fluorescence was detected at 397 nm following excitation at 365 nm. Phase-contrast images were obtained with the same microscopy setup.

Western blotting analysis
-------------------------

1.0 × 10^6^ cells were scraped and lysed in Lysis buffer composed of 20 mM HEPES, 100 mM NaCl, 5 mM EDTA, 1% NP-40+Halt Protease & Phosphatase Inhibitor Cocktail (Thermo Scientific, Fisher Scientific, Loughborough, UK). Protein quantification was performed with Bio-Rad Protein Assay (Bio-Rad, Hemel Hempstead, UK) and 50 *μ*g of proteins was resolved on 5--10% gradient SDS-PAGE. Densitometric analysis was performed with Quantity One program (Bio-Rad).

Calcium imaging
---------------

Cells were loaded with 3 *μ*M of Fluo4-AM in Krebs-Ringer modified buffer (KRB) (136 mM NaCl, 20 mM HEPES, 5.5 mM glucose, 1.2 mM KH~2~PO~4~, 1.2 mM MgSO~4~, 5 mM NaHCO~3~, 1.8 mM KCl, 2 mM CaCl~2~ pH 7.4) supplemented with 0.01% pluronic acid for 30 min at 37 °C. After de-esterification (30 min at 37 °C), the coverslips were placed in a perfusing chamber, mounted on the stage of an inverted confocal microscope (Nikon Eclipse TE300: Nikon Instruments Europe BV, Amstelveen, Netherlands). Cells were superfused with KRB at 8 ml/min and maintained at 37 °C. Cells were excited at 488 nm excitation laser (emitted light filtered at 515±30 nm) and viewed using a × 20 dry objective (NA 0.5). Fluorescent images were taken from the middle of the cell volume, and time series acquisition was controlled with EZ-C1 Nikon software. Drugs were applied by superfusion. To quantify the differences in the peaks of Ca^2+^ transients, the values were normalized using the formula (*F*~i~−*F*~0~)/*F*~0~ (where *F*~i~ is the value of fluorescence recorded during the stimulation and *F*~0~ is the basal value of fluorescence recorded).

Reagents
--------

Amyloid *β* protein (1--42) hydrochloride salt (H-6466) was purchased from Bachem AG (Budendorf, Switzerland). Rabbit polyclonal antibody anti-InsP~3~R1 (AB5882) and rabbit polyclonal antibody anti-mGluR5 (AB5675) were from Millipore (Walford, UK); goat antibody anti-GFAP (SAB2500462) and adenosine triphosphate (ATP) were from Sigma; anti-*β*−actin HRP-conjugated antibody from Santa Cruz Biotechnology (Heidelberg, Germany), Sc-47778 HRP; peroxidase-conjugated secondary antibodies were from GE Healthcare (Bucks, UK); (S)-3,5-dihydroxyphenylglycine (DHPG) was from Tocris Bioscience (Bristol, UK); Fluo4-AM calcium probe (F14201) and Pluronic F-127 (P3000MP) were from Invitrogen (Paisley, UK).

Statistical analysis
--------------------

For multiple comparisons ANOVA analysis was used with Prism Graph Pad software. Between two groups Student\'s *t*-test or one-sample *t*-test was used. Differences were considered significant at *P*\<0.05.
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![Morphological differences between cultured astrocytes derived from EC and hippocampus. (**a**) Microphotographs show the phase-contrast images of live (non fixed) hippocampal cultured astrocytes (left) and EC cultured astrocytes (right) at 4 days *in vitro*. (**b**) Representative images of GFAP-stained hippocampal and EC astrocytes derived from non-Tg control and 3xTg-AD model animals. Left panels represent images of GFAP immunofluorescence of stained cells, whereas right panels show merged images of phase-contrast images (gray) and GFAP/DAPI (green/blue) staining obtained from the same cells and fields of view. (**c**) *In situ* images of GFAP-stained hippocampal and EC astrocytes; the cells were GFAP labelled in slices obtained from 6-month-old non-Tg animals. For technical details, see Olabarria *et al.*^[@bib15]^ and Yeh *et al.*^[@bib22]^ (**d**) Quantification of the percentage of thin, long needle-shaped and flat or stellate cells in cultures prepared from hippocampus and the EC; *n*=320, from four different cultures \*\**P*\<0.01](cddis2013145f1){#fig1}

![A*β* oligomers differentially affect the expression of mGluR5 and InsP~3~R1 in astrocytes from different regions of the brain. (**a**) Representative immunostaining of mGluR5 and InsP~3~R1 (green) and DAPI-staining for nuclei (blue) in astrocytes cultured from EC and hippocampus of non-Tg mice at 7 days *in vitro*. (**b**) Quantifications of the expression (western blot analysis) of mGluR5 and InsP~3~R1 expression in control cells and cells treated with 100 nM of A*β* for 72 h in hippocampal cultures (upper graph) and EC cultures (lower graph) (\**P*\<0.05, averages of seven cultures for non-Tg mice and four cultures for 3xTg-AD mice)](cddis2013145f2){#fig2}

![Effect of A*β* treatment on metabotropic glutamatergic Ca^2+^ signalling in EC and hippocampal astrocytes from non-Tg and 3xTg-AD mice. (**a** and **b**) Representative traces of DHPG-induced Ca^2+^ responses in hippocampus and EC in control and in A*β*-treated cells derived from non-Tg mice, and control and A*β*-treated cells derived from 3xTg-AD mice (*n*=30 cells for each experimental protocol). The cells were exposed to 100 nM of A*β* for 72 h and then loaded with Fluo4-AM, and stimulated with 100 *μ*M DHPG for 15 s. (**c**) Mean values for integrals of \[Ca^2+^\]~i~ transients induced by DHPG stimulation (*n*=150 cells from five different cultures for each experimental protocol)](cddis2013145f3){#fig3}

![Effect of A*β* treatment on metabotropic purinergic Ca^2+^ signalling in EC and hippocampal astrocytes from non-Tg and 3xTg-AD mice. (**a** and **b**) Representative traces of ATP-induced Ca^2+^ responses in hippocampus and EC in control cells and in A*β*-treated cells derived from non-Tg mice, and control and A*β*-treated cells derived from 3xTg-AD mice (*n*=30 cells for each experimental protocol). The cells were exposed to 100 nM of A*β* for 72 h and then loaded with Fluo4-AM, and stimulated with 100 *μ*M ATP for 15 s. (**c**) Mean values for integrals of \[Ca^2+^\]~i~ transients induced by ATP stimulation (*n*=150 cells from five different cultures for each experimental protocol)](cddis2013145f4){#fig4}
